エルタペネム HYDROCHLORIDE

エルタペネム HYDROCHLORIDE 化学構造式
153832-46-3
CAS番号.
153832-46-3
化学名:
エルタペネム HYDROCHLORIDE
别名:
エルタペネム HYDROCHLORIDE;エルタペネム;(4R,5S,6S)-3-{[(3S,5S)-5-[(3-カルボキシフェニル)カルバモイル]ピロリジン-3-イル]スルファニル}-6-[(1R)-1-ヒドロキシエチル]-4-メチル-7-オキソ-1-アザビシクロ[3.2.0]ヘプタ-2-エン-2-カルボン酸;(4R,5S,6S)-3-[[(3S,5S)-5-[(3-カルボキシフェニル)カルバモイル]ピロリジン-3-イル]チオ]-4-メチル-6-[(R)-1-ヒドロキシエチル]-7-オキソ-1-アザビシクロ[3.2.0]ヘプタ-2-エン-2-カルボン酸
英語名:
Ertapenem
英語别名:
Ertapenem hydrochloride;MK-0826;EOS-61119;ERTAPENEM;Ertapenem D4;Ertapenem Powder;Ertapenem Monomer;Ertapenem USP/EP/BP;ERTAPENEM(FORR&DONLY);ErtapenemDiscontinued See E635000
CBNumber:
CB0722982
化学式:
C22H25N3O7S
分子量:
475.51
MOL File:
153832-46-3.mol

エルタペネム HYDROCHLORIDE 物理性質

沸点 :
813.9±65.0 °C(Predicted)
比重(密度) :
1.55±0.1 g/cm3(Predicted)
貯蔵温度 :
2-8°C
溶解性:
soluble in DMSO, Methanol
酸解離定数(Pka):
4.03±0.10(Predicted)
外見 :
Foam
色:
Brown
InChIKey:
JUZNIMUFDBIJCM-ANEDZVCMSA-N
SMILES:
N12[C@@]([H])([C@@H]([C@H](O)C)C1=O)[C@@H](C)C(S[C@H]1C[C@@H](C(NC3=CC=CC(C(O)=O)=C3)=O)NC1)=C2C(O)=O
CAS データベース:
153832-46-3
安全性情報
  • リスクと安全性に関する声明
  • 危険有害性情報のコード(GHS)
有毒物質データの 153832-46-3(Hazardous Substances Data)
絵表示(GHS) Exclamation Mark (GHS07)
注意喚起語 警告
危険有害性情報
コード 危険有害性情報 危険有害性クラス 区分 注意喚起語 シンボル P コード
H302 飲み込むと有害 急性毒性、経口 4 警告 P264, P270, P301+P312, P330, P501
H315 皮膚刺激 皮膚腐食性/刺激性 2 警告 P264, P280, P302+P352, P321,P332+P313, P362
H319 強い眼刺激 眼に対する重篤な損傷性/眼刺激 性 2A 警告 P264, P280, P305+P351+P338,P337+P313P
H335 呼吸器への刺激のおそれ 特定標的臓器毒性、単回暴露; 気道刺激性 3 警告
注意書き
P261 粉じん/煙/ガス/ミスト/蒸気/スプレーの吸入を避ける こと。
P305+P351+P338 眼に入った場合:水で数分間注意深く洗うこと。次にコ ンタクトレンズを着用していて容易に外せる場合は外す こと。その後も洗浄を続けること。

エルタペネム HYDROCHLORIDE 価格 もっと(2)

メーカー 製品番号 製品説明 CAS番号 包装 価格 更新時間 購入
富士フイルム和光純薬株式会社(wako) W01MAS098876 エルタペネム hydrochloride
Ertapenem hydrochloride
153832-46-3 250mg ¥364800 2024-03-01 購入
富士フイルム和光純薬株式会社(wako) W01MAS098876 エルタペネム hydrochloride
Ertapenem hydrochloride
153832-46-3 1g ¥1094300 2024-03-01 購入

エルタペネム HYDROCHLORIDE 化学特性,用途語,生産方法

効能

抗生物質, 細胞壁合成阻害薬

説明

Ertapenem is another synthetic carbapenem with a rather complex side chain at C-3. It is used once daily parenterally, with special application against anaerobes. As with meropenem, the 4-β-methyl group confers stability toward dehydropeptidase-1 It is not active against pseudomonads or acinetobacteria and, therefore, should not be substituted for imipenem or meropenem. It is relatively strongly bound to serum proteins, so it has a prolonged half-life, making it more convenient to use than the other carbapenems when its spectrum warrants this. Its reported indications include complicated intra-abdominal and complicated skin/skin structure infections caused by sensitive organisms (for intra-abdominal: Escheri chia coli, Clostri di um clostri doforme, Bacteroi des fragilis, and Peptostreptococcus sp; for skin/skin structures: Staphylococcus aureus (methicillin-susceptible strains), Streptococcus pyogenes, E.coli, or Peptostreptococcus sp.). It can be administered once daily.

使用

Ertapenem is a long-acting parenteral cabapenem. Ertapenem has bactericidal activity against a variety of gram-negative pathogens, some gram positive strains, and Haemopilus influenzae. Ertapenem has shown to inactivate L,D-transpeptidase, an enzyme responsible for in vitro cross-linking of Mycobacterium tuberculosis peptidoglycan.

定義

ChEBI: Meropenem in which the one of the two methyl groups attached to the amide nitrogen is replaced by hydrogen while the other is replaced by a 3-carboxyphenyl group. The sodium salt is used for the treatment of moderate to severe susceptible infections includ ng intra-abdominal and acute gynaecological infections, pneumonia, and infections of the skin and of the urinary tract.

抗菌性

Activity against aerobic and anaerobic pathogens is comparable to that of imipenem: MIC values for Gramnegative bacilli (with the exception of Ps. aeruginosa) are generally lower and those for Gram-positive cocci higher.
Ertapenem is stable to most serine β-lactamases, but is hydrolyzed by serine carbapenemases and metallo- β-lactamases.

一般的な説明

Ertapenem (Invanz, for injection) is a synthetic 1-β-methylcarbapenem that is structurally related to β-lactam antibiotics,particularly the thienamycin group. Its mechanism ofaction is the same as that of other β-lactam antibiotics. Thestructure resists β-lactamases and dehydropeptidases.
Ertapenem is indicated for the treatment of moderate tosevere infections caused by susceptible strains causing complicatedintra-abdominal infections such as Escherichia,Clostridium, Peptostreptococcus, and Bacteroides. Theantibiotic is also indicated for complicated skin and skinstructure infections including diabetic foot infections (withoutosteomyelitis). Treatable strains include Staphylococcus(MSSA), Streptococcus, Escherichia, Klebsiella, Proteus,and Bacteroides. Ertapenem is also indicated for community-acquired pneumonia caused by S. pneumoniae,Haemophilus infljuenzae, and M. catarrhalis. Complicatedurinary tract infections and acute pelvic infections round outthe indications for ertapenem.

薬物動態学

Cmax 1 g intramuscular: c. 67 mg/L after 2 h
1 g intravenous infusion (30 min): c. 155 mg/L end infusion
Plasma half-life: c. 4 h
Volume of distribution: c. 0.12 L/kg (steady state)
Plasma protein binding: 85–95%
Absorption after intramuscular injection is essentially complete with 90% bioavailability. The modestly extended plasma half-life allows once-daily dosing.
Excretion is predominantly by the renal route, about 80% being recovered in the urine within 24 h. About 40% is eliminated unchanged, the rest as a biologically inactive ringopened metabolite. Dosage should be reduced in severe renal impairment.

臨床応用

Complicated intra-abdominal infections
Complicated skin and skin structure infections, including diabetic foot
infections without osteomyelitis
Community acquired pneumonia
Complicated urinary tract infections including pyelonephritis
Acute pelvic infections including postpartum endomyometritis, septic
abortion and postsurgical gynecologic infections
Prophylaxis of surgical site infection following elective colorectal surgery

副作用

Ertapenem appears to be generally well tolerated. The most common drug-related adverse experiences are diarrhea (5.5%), infused vein complication (3.7%), nausea (3.1%), headache (2.2%), vaginitis (2.1%), phlebitis/thrombophlebitis (1.3%) and vomiting (1.1%). Seizures have occasionally been reported (0.5%) in patients with a history of disorders of the CNS.

エルタペネム HYDROCHLORIDE 上流と下流の製品情報

原材料

準備製品


エルタペネム HYDROCHLORIDE 生産企業

Global( 186)Suppliers
名前 電話番号 電子メール 国籍 製品カタログ 優位度
Suizhou HongQi Chemical Corporation Limited 0722-3257376 13026100080;13235518175;
774811011@qq.com China 60 55
wangyubin@starunimed.com 18328380615
youchaochris@starunimed.com China 489 58
J & K SCIENTIFIC LTD. 18210857532 18210857532
jkinfo@jkchemical.com China 96815 76
shilang(zhuoli group)-pharma(nanjing) co.,ltd. 86-25-87797880,81,82 -809
shilang@shilang-pharma.com China 40 55
Beijing HwrkChemical Technology Co., Ltd 89508211 18501085097
sales.bj@hwrkchemical.com China 9407 55
Adamas Reagent, Ltd. 400-6009262 15618770481
yhx@titansci.com China 14098 59
LGM Pharma 1-(800)-881-8210
inquiries@lgmpharma.com United States 2110 70
Shanghai Longsheng chemical Co.,Ltd. 58099637 13585536065
sales@shlschem.com China 9880 59
XiaoGan ShenYuan ChemPharm co,ltd 15527621225; 15527621225
1791901229@qq.com China 6739 52
China Langchem Inc. 0086-21-58956006
China 7798 57

153832-46-3(エルタペネム HYDROCHLORIDE)キーワード:


  • 153832-46-3
  • ERTAPENEM
  • (4r,5r,6s)-3-[(3s,5s)-5-[(3-carboxyphenyl)carbamoyl]pyrrolidin-3-yl]sulfanyl-6-(1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
  • ERTAPENEM(FORR&DONLY)
  • (4R,5S,6S)-3-{[(3S,5S)-5-[(3-carboxyphenyl)carbaMoyl]pyrrolidin-3-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-4-Methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid
  • 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid,3-[[(3S,5S)-5-[[(3-carboxyphenyl)aMino]carbonyl]-3-pyrrolidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-Methyl-7-oxo-,(4R,5S,6S)-
  • sodium(4R,5S,6S)-3-(((3S,5S)-5-((3-carboxylatophenyl)carbamoyl)pyrrolidin-1-ium-3-yl)thio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
  • EOS-61119
  • ErtapenemDiscontinued See E635000
  • MK-0826
  • Ertapenem USP/EP/BP
  • Ertapenem D4
  • Ertapenem Powder
  • Benzaldehyde,5-chloro-3-(1,1-dimethylethyl)-7-hydroxy-
  • Ertapenem Monomer
  • Ertapenem hydrochloride
  • エルタペネム HYDROCHLORIDE
  • エルタペネム
  • (4R,5S,6S)-3-{[(3S,5S)-5-[(3-カルボキシフェニル)カルバモイル]ピロリジン-3-イル]スルファニル}-6-[(1R)-1-ヒドロキシエチル]-4-メチル-7-オキソ-1-アザビシクロ[3.2.0]ヘプタ-2-エン-2-カルボン酸
  • (4R,5S,6S)-3-[[(3S,5S)-5-[(3-カルボキシフェニル)カルバモイル]ピロリジン-3-イル]チオ]-4-メチル-6-[(R)-1-ヒドロキシエチル]-7-オキソ-1-アザビシクロ[3.2.0]ヘプタ-2-エン-2-カルボン酸
Copyright 2017 © ChemicalBook. All rights reserved